Pemetrexed Pfizer 100 mg powder for concentrate for solution for infusion

DRUG3 trials

Sponsors

Summit Therapeutics Inc., Glaxosmithkline Research & Development Limited, European Organisation For Research And Treatment Of Cancer

Conditions

Lung CancerNon-Small CellNon-small cell lung cancerPatients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment

Phase 2

A RANDOMIZED, PHASE 2, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF DOSTARLIMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

CompletedCTIS2023-505894-33-00

Glaxosmithkline Research & Development LimitedLung Cancer, Non-Small Cell

Start: 2020-11-25End: 2024-09-10Target: 114Updated: 2024-02-29

EORTC-2456-LCG-BTG: A randomized phase II study evaluating upfront SRT to all brain metastases followed by ivonescimab plus chemotherapy versus upfront ivonescimab plus chemotherapy in patients with asymptomatic active brain metastases from NSCLC.

Not yet recruitingCTIS2025-522985-60-00

European Organisation For Research And Treatment Of CancerNon-small cell lung cancer

Target: 34Updated: 2026-10-20

Phase 3

A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)

Active, not recruitingCTIS2023-504434-22-00

Summit Therapeutics Inc.Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment

Start: 2023-10-03Target: 45Updated: 2025-12-16